title: Initial safety experience of abciximab and heparin for acute ischemic stroke.
authors.affiliation: Baylor College of Medicine and the Michael E. DeBakey VA Medical Center, Houston, TX 77030, USA. pmandava@bcm.tmc.edu
authors.forename: Pitchaiah
authors.initials: P
authors.lastname: Mandava
authors.forename: Scott D
authors.initials: SD
authors.lastname: Lick
authors.forename: M A
authors.initials: MA
authors.lastname: Rahman
authors.forename: Hans
authors.initials: H
authors.lastname: Langsjoen
authors.forename: K V
authors.initials: KV
authors.lastname: Reddy
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Nelson
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Kent
mesh_terms: D000077284:Abciximab; D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D002545:Brain Ischemia / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D020521:Stroke / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000925:Anticoagulants; D007140:Immunoglobulin Fab Fragments; D006493:Heparin; D000077284:Abciximab